ISDA

Deposition Date 2017-05-01

Release Date 2017-07-12

Last Version Date 2024-10-30

Entry Detail

PDB ID:

5Q0E

Keywords:

HYDROLASE/HYDROLASE inhibitor

Title:

FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4S,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-4-methyl-2-oxo-1,3,4,5,6,7,8,10-octahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.12 Å

R-Value Free:

0.19

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

P 32 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Coagulation factor XI
Gene (Uniprot):F11
Chain IDs:A
Chain Length:244
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P03951 Pfam ID:PF00089 EC:3.4.21.27

Ligand Molecules

9FD

EDO

SO4

Primary Citation

Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency.

Corte, J.R, Yang, W, Fang, T, Wang, Y, Osuna, H, Lai, A, Ewing, W.R, Rossi, K.A, Myers, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Harper, T.W, Bozarth, J.M, Wu, Y, Luettgen, J.M, Seiffert, D.A, Quan, M.L, Wexler, R.R, Lam, P.Y.S, Quan, M.L, Wong, P.C, Wang, C, Woerner, F, Smallheer, J.M, Barbera, F.A, Bozarth, J.M, Brown, R.L, Harpel, M.R, Luettgen, J.M, Morin, P.E, Peterson, T, Ramamurthy, V, Rendina, A.R, Rossi, K.A, Watson, C.A, Wei, A, Zhang, G, Seiffert, D, Wexler, R.R, Hangeland, J.J, Friends, T.J, Rossi, K.A, Smallheer, J.M, Wang, C, Sun, Z, Corte, J.R, Fang, T, Wong, P.C, Rendina, A.R, Barbera, F.A, Bozarth, J.M, Luettgen, J.M, Watson, C.A, Zhang, G, Wei, A, Ramamurthy, V, Morin, P.E, Bisacchi, G.S, Subramaniam, S, Arunachalam, P, Mathur, A, Seiffert, D.A, Wexler, R.R, Quan, M.L, Corte, J.R, Fang, T, Hangeland, J.J, Friends, T.J, Rendina, A.R, Luettgen, J.M, Bozarth, J.M, Barbera, F.A, Rossi, K.A, Wei, A, Ramamurthy, V, Morin, P.E, Seiffert, D.A, Wexler, R.R, Quan, M.L, Pinto, D.J, Smallheer, J.M, Corte, J.R, Austin, E.J, Wang, C, Fang, T, Smith, L.M, Rossi, K.A, Rendina, A.R, Bozarth, J.M, Zhang, G, Wei, A, Ramamurthy, V, Sheriff, S, Myers, J.E, Morin, P.E, Luettgen, J.M, Seiffert, D.A, Quan, M.L, Wexler, R.R, Hu, Z, Wong, P.C, Gilligan, P.J, Han, W, Pabbisetty, K.B, Bozarth, J.M, Crain, E.J, Harper, T, Luettgen, J.M, Myers, J.E, Ramamurthy, V, Rossi, K.A, Sheriff, S, Watson, C.A, Wei, A, Zheng, J.J, Seiffert, D.A, Wexler, R.R, Quan, M.L, Smith, L.M, Orwat, M.J, Hu, Z, Han, W, Wang, C, Rossi, K.A, Gilligan, P.J, Pabbisetty, K.B, Osuna, H, Corte, J.R, Rendina, A.R, Luettgen, J.M, Wong, P.C, Narayanan, R, Harper, T.W, Bozarth, J.M, Crain, E.J, Wei, A, Ramamurthy, V, Morin, P.E, Xin, B, Zheng, J, Seiffert, D.A, Quan, M.L, Lam, P.Y, Wexler, R.R, Pinto, D.J, Corte, J.R, Fang, T, Pinto, D.J, Orwat, M.J, Rendina, A.R, Luettgen, J.M, Rossi, K.A, Wei, A, Ramamurthy, V, Myers, J.E, Sheriff, S, Narayanan, R, Harper, T.W, Zheng, J.J, Li, Y.X, Seiffert, D.A, Wexler, R.R, Quan, M.L, Corte, J.R, Fang, T, Osuna, H, Pinto, D.J, Rossi, K.A, Myers, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Harper, T.W, Bozarth, J.M, Wu, Y, Luettgen, J.M, Seiffert, D.A, Decicco, C.P, Wexler, R.R, Quan, M.L.Show

Bioorg. Med. Chem. Lett. 27 3833 3839 (2017)

PMID: 28687203 DOI: 10.1016/j.bmcl.2017.06.058

Abstact

Optimization of macrocyclic inhibitors of FXIa is described which focused on modifications to both the macrocyclic linker and the P1 group. Increases in potency were discovered through interactions with a key hydrophobic region near the S1 prime pocket by substitution of the macrocyclic linker with small alkyl groups. Both the position of substitution and the absolute stereochemistry of the alkyl groups on the macrocyclic linker which led to improved potency varied depending on the ring size of the macrocycle. Replacement of the chlorophenyltetrazole cinnamide P1 in these optimized macrocycles reduced the polar surface area and improved the oral bioavailability for the series, albeit at the cost of a decrease in potency.

Legend

Protein

Chemical

Disease

Primary Citation of related structures